<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680002</url>
  </required_header>
  <id_info>
    <org_study_id>BARDA CSN 15-0001</org_study_id>
    <nct_id>NCT02680002</nct_id>
  </id_info>
  <brief_title>Assess the Safety &amp; Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With &amp; Without Stored MF59 Adjuvant</brief_title>
  <official_title>Randomized, Double-Blinded, Phase 2 Study to Assess Safety &amp; Immunogenicity of Stored Inactivated Monovalent Influenza A/Vietnam/H5N1 Virus Vaccine Administered Intramuscularly at Different Dose Levels Given With &amp; Without Stored MF59® Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomedical Advanced Research and Development Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the usability of long-term stored H5N1 antigen&#xD;
      and adjuvant. The study is designed to assist in stockpile management by assessing the&#xD;
      safety, reactogenicity, and immunogenicity long-term stored influenza A/Vietnam/H5N1 vaccine&#xD;
      when administered with or without MF59® adjuvant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blinded, Phase 2 study to assess the safety and&#xD;
      immunogenicity of 2 doses of long-term stored inactivated monovalent influenza A/Vietnam/H5N1&#xD;
      virus vaccine administered intramuscularly with or without MF59 adjuvant in healthy males and&#xD;
      nonpregnant females, aged 18 to 49 years, inclusive. This study is designed to assist in&#xD;
      stockpile management and will assess the usability of long-term stored H5N1 antigen (ie,&#xD;
      stored &gt;10 years) and adjuvant (ie, stored &gt;5 years).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 13, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</measure>
    <time_frame>Days 0 to 7</time_frame>
    <description>Occurence of mild, moderate, or severe solicited local symptoms during the 7 days (Days 0 to 7) following Dose 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</measure>
    <time_frame>Days 21 to 28</time_frame>
    <description>Occurence of mild, moderate, or severe solicited local symptoms during the 7 days (Days 21 to 28) following Dose 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With &gt;=1 (More Than or Equal to 1) Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</measure>
    <time_frame>Days 0 to 7</time_frame>
    <description>Number of participants with &gt;=1 mild, moderate, or severe solicited local symptoms during the 7 days (Days 0 to 7) following Dose 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With &gt;=1 (More Than or Equal to 1) Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</measure>
    <time_frame>Days 21 to 28</time_frame>
    <description>Number of participants with &gt;=1 mild, moderate, or severe solicited local symptoms during the 7 days (Days 21 to 29) following Dose 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Mild, Moderate, or Severe Solicited Systemic Reactogenicity Symptoms During the 7 Days After Each Vaccination.</measure>
    <time_frame>Days 0 to 7</time_frame>
    <description>Number of participants with mild, moderate, or severe solicited systemic reactogenicity adverse events during the 7 days (Days 0 to 7) following Dose 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With of Mild, Moderate, or Severe Solicited Systemic Reactogenicity Symptoms During the 7 Days After Each Vaccination.</measure>
    <time_frame>Days 21 to 28</time_frame>
    <description>Number of participants with of mild, moderate, or severe solicited systemic reactogenicity adverse events during the 7 days (Days 21 to 28) following Dose 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibody</measure>
    <time_frame>21 days after receipt of second dose of vaccine (Day 42) (plus or minus 3 days)</time_frame>
    <description>Geometric Mean Titer (GMT) of hemagglutination inhibition (HAI) antibody against A/Vietnam/H5N1 antigen in each study group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vaccine-associated Serious Adverse Events (SAE) or Adverse Event of Special Interests (AESI)</measure>
    <time_frame>First vaccination through 13 months</time_frame>
    <description>Number of participants with vaccine-associated serious adverse events (SAE) or adverse event of special interests (AESI) and occurence of AESIs or AEs leading to study withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events of Special Interest (AESI) or Adverse Events (AE) Leading to Study Withdrawal.</measure>
    <time_frame>First vaccination through approximately 13 months after first vaccination</time_frame>
    <description>Number of participants with adverse events of special interest (AESI) or adverse events (AE) leading to study withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events (AE)</measure>
    <time_frame>Day 0 (Visit 1) through Day 201 (Visit 8)</time_frame>
    <description>Number of participants with unsolicited adverse events (AE) through Visit 8 (Day 201)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Unsolicited Adverse Events (AE)</measure>
    <time_frame>21 days following each vaccination (Days 0-21, &gt;21 Days)</time_frame>
    <description>Frequency of unsolicited adverse events (AE) for 21 days following Dose 1 (Days 0-21) and after Dose 2 (&gt;21 Days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Clinical Safety Laboratory AEs</measure>
    <time_frame>7 and 21 days after each vaccination (Days 0, 7, 21, 28, and 42)</time_frame>
    <description>Occurrence of clinical safety laboratory AEs at 7 and 21 days after each vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT (Geometric Mean Titers) of Serum HAI (Hemagglutination Inhibition) Antibodies</measure>
    <time_frame>Day 0 (Visit 1), Day 21 (Visit 4), Day 28 (Visit 6), Day 201 (Visit 8)</time_frame>
    <description>Overall GMTs of HAI antibodies at baseline (Day 0) and Days 21, 28 and 201</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT (Geometric Mean Titers) of Serum Microneutralization (MN) Antibodies</measure>
    <time_frame>Day 0 (Visit 1), Day 21 (Visit 4), Day 28 (Visit 6), Day 42 (Visit 7), Day 201 (Visit 8)</time_frame>
    <description>GMT of serum MN antibodies at baseline (Day 0) and Days 21, 28, 42 and 201</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HAI (Hemagglutination Inhibition) Titer of at Least 1:40</measure>
    <time_frame>Days 0 (Visit 1), 21 (Visit 4, +1day), 28 (Visit 6, +1 day), 42 (Visit 7, plus or minus 3 days), and 201 (Visit 8, plus or minus 7 days)</time_frame>
    <description>Proportion of participants achieving a serum HAI titer of at least 1:40 against the A/Vietnam/H5N1 antigen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate (SCR) for Hemagglutination Inhibition (HAI) Antibodies</measure>
    <time_frame>Days 21, 28, 42, and 201</time_frame>
    <description>Defined as proportion of subjects achieving either a prevaccination HAI titer of &lt;1:10 and postvaccination titer of at least 1:40 or a prevaccination HAI titer of at least 1:10 and a 4-fold or greater increase of HAI postvaccination antibody titers against the A/Vietnam/H5N1 antigen; if baseline HAI titer is undetectable, it will be assigned a vaue of half the lower limit of detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate (SCR) for Microneutralization (MN) Antibodies</measure>
    <time_frame>Days 21, 28, 42, and 201</time_frame>
    <description>Defined as proportion of subjects achieving either a prevaccination MN titer of &lt;1:10 and postvaccination titer of at least 1:40 or a prevaccination MN titer of at least 1:10 and a 4-fold or greater increase of MN postvaccination antibody titers against the A/Vietnam/H5N1 antigen; if baseline MN titer is undetectable, it will be assigned a vaue of half the lower limit of detection.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>A/Vietnam/H5N1 Influenza Virus</condition>
  <arm_group>
    <arm_group_label>7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mcg H5N1 (monobulk) Plus MF59 (monobulk)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 mcg H5N1 (monobulk) Plus MF59 (vials)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mcg H5N1 (monobulk) Plus MF59 (vials)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg H5N1 (monobulk) without MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90 mcg H5N1 (vials) without MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7.5 mcg H5N1 (stored as monobulk)</intervention_name>
    <arm_group_label>7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)</arm_group_label>
    <arm_group_label>7.5 mcg H5N1 (monobulk) Plus MF59 (vials)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>15 mcg H5N1 (stored as monobulk)</intervention_name>
    <arm_group_label>15 mcg H5N1 (monobulk) Plus MF59 (monobulk)</arm_group_label>
    <arm_group_label>15 mcg H5N1 (monobulk) Plus MF59 (vials)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>90 mcg H5N1 (stored as monobulk)</intervention_name>
    <arm_group_label>90 mcg H5N1 (monobulk) without MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>90 mcg H5N1 (stored in vials)</intervention_name>
    <arm_group_label>90 mcg H5N1 (vials) without MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MF59</intervention_name>
    <arm_group_label>15 mcg H5N1 (monobulk) Plus MF59 (vials)</arm_group_label>
    <arm_group_label>7.5 mcg H5N1 (monobulk) Plus MF59 (vials)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MF59 (stored as monobulk)</intervention_name>
    <arm_group_label>15 mcg H5N1 (monobulk) Plus MF59 (monobulk)</arm_group_label>
    <arm_group_label>7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or nonpregnant female&#xD;
&#xD;
          -  Provide written informed consent prior to study-related procedures&#xD;
&#xD;
          -  Stable health status&#xD;
&#xD;
          -  Access to consistent and reliable means of telephone contact&#xD;
&#xD;
          -  Able to understand and comply with planned study procedures&#xD;
&#xD;
          -  Agree to stay in contact with site, and no plans to move from study area for study&#xD;
             duration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to eggs, other vaccine components, or squalene-based adjuvants&#xD;
&#xD;
          -  Women with positive pregnancy test within 24 hours of vaccination, or are&#xD;
             breastfeeding&#xD;
&#xD;
          -  Females of childbearing potential who refuse acceptable birth control, if sexually&#xD;
             active, have not used birth control for 2 months prior to study entry&#xD;
&#xD;
          -  Have immunosuppression or use anticancer chemotherapy or radiation therapy within&#xD;
             preceding 36 months&#xD;
&#xD;
          -  Have an active neoplastic disease or history of hematologic malignancy&#xD;
&#xD;
          -  Have long term use (≥14 consecutive days) of glucocorticoids (&gt;20 mg/day) or high-dose&#xD;
             inhaled steroids (&gt;800 mcg/day) within preceding 6 months&#xD;
&#xD;
          -  Diagnosis of schizophrenia, bipolar disease, or major psychiatric diagnosis&#xD;
&#xD;
          -  Have been hospitalized for psychiatric illness, attempted suicide or deemed danger to&#xD;
             self or others within past 10 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Ridge Family Practice</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Researcch Associates, Inc.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/30553570</url>
    <description>Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)</description>
  </link>
  <reference>
    <citation>Oshansky CM, Zhou J, Gao Y, Schweinle JE, Biscardi K, DeBeauchamp J, Pavetto C, Wollish A; BRITE Study Coordination Team, Webby RJ, Cioce V, Donis RO, Bright RA. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). Vaccine. 2019 Jan 14;37(3):435-443. doi: 10.1016/j.vaccine.2018.11.069. Epub 2018 Dec 12.</citation>
    <PMID>30553570</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <results_first_submitted>April 17, 2019</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Influenza in Birds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study results will be posted on publicly available clinical trial registers.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened and enrolled at 6 sites in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
        </group>
        <group group_id="P2">
          <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant MF59 adjuvant</description>
        </group>
        <group group_id="P3">
          <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant&#xD;
7.5 mcg H5N1 (stored as monobulk)&#xD;
MF59</description>
        </group>
        <group group_id="P4">
          <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
        </group>
        <group group_id="P5">
          <title>90 mcg H5N1 (Monobulk) Without MF59</title>
          <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
        </group>
        <group group_id="P6">
          <title>90 mcg H5N1 (Vials) Without MF59</title>
          <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 0 (Dose 1)</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 21 (Dose 2)</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="65"/>
                <participants group_id="P6" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Day 201</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Visit 8 (Day 201)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: Number of participants receiving at least one dose (Dose 1/Day 0) of the investigational product.</population>
      <group_list>
        <group group_id="B1">
          <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
        </group>
        <group group_id="B2">
          <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
        </group>
        <group group_id="B3">
          <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
        </group>
        <group group_id="B4">
          <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
        </group>
        <group group_id="B5">
          <title>90 mcg H5N1 (Monobulk) Without MF59</title>
          <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
        </group>
        <group group_id="B6">
          <title>90 mcg H5N1 (Vials) Without MF59</title>
          <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="71"/>
            <count group_id="B5" value="70"/>
            <count group_id="B6" value="68"/>
            <count group_id="B7" value="419"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to &lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to &lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="8.02"/>
                    <measurement group_id="B2" value="36.8" spread="8.47"/>
                    <measurement group_id="B3" value="38.1" spread="8.37"/>
                    <measurement group_id="B4" value="35.7" spread="8.25"/>
                    <measurement group_id="B5" value="34.9" spread="8.62"/>
                    <measurement group_id="B6" value="36.0" spread="7.60"/>
                    <measurement group_id="B7" value="36.4" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" lower_limit="21" upper_limit="49"/>
                    <measurement group_id="B2" value="37.5" lower_limit="20" upper_limit="48"/>
                    <measurement group_id="B3" value="38.5" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B4" value="37.0" lower_limit="18" upper_limit="48"/>
                    <measurement group_id="B5" value="37.0" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B6" value="35.0" lower_limit="18" upper_limit="49"/>
                    <measurement group_id="B7" value="37" lower_limit="18" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="71"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="68"/>
                    <measurement group_id="B7" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.79" spread="9.29"/>
                    <measurement group_id="B2" value="30.76" spread="8.59"/>
                    <measurement group_id="B3" value="31.75" spread="8.35"/>
                    <measurement group_id="B4" value="30.50" spread="8.15"/>
                    <measurement group_id="B5" value="31.76" spread="8.13"/>
                    <measurement group_id="B6" value="31.57" spread="9.27"/>
                    <measurement group_id="B7" value="31.52" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.93" lower_limit="20.23" upper_limit="63.66"/>
                    <measurement group_id="B2" value="28.95" lower_limit="17.76" upper_limit="61.42"/>
                    <measurement group_id="B3" value="29.79" lower_limit="17.50" upper_limit="56.96"/>
                    <measurement group_id="B4" value="28.08" lower_limit="13.89" upper_limit="53.45"/>
                    <measurement group_id="B5" value="30.21" lower_limit="20.33" upper_limit="54.13"/>
                    <measurement group_id="B6" value="30.84" lower_limit="17.89" upper_limit="71.43"/>
                    <measurement group_id="B7" value="29.70" lower_limit="17.50" upper_limit="71.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
        <description>Occurence of mild, moderate, or severe solicited local symptoms during the 7 days (Days 0 to 7) following Dose 1</description>
        <time_frame>Days 0 to 7</time_frame>
        <population>Participants who received Dose 1 (Day 0), analyzed up to Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
          <description>Occurence of mild, moderate, or severe solicited local symptoms during the 7 days (Days 0 to 7) following Dose 1</description>
          <population>Participants who received Dose 1 (Day 0), analyzed up to Day 7.</population>
          <units>occurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number solicited local AEs (Adverse Events)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Mild solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Moderate solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Severe solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
        <description>Occurence of mild, moderate, or severe solicited local symptoms during the 7 days (Days 21 to 28) following Dose 2</description>
        <time_frame>Days 21 to 28</time_frame>
        <population>Participants who received Dose 2 (Day 21), analyzed up to Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Occurences of Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
          <description>Occurence of mild, moderate, or severe solicited local symptoms during the 7 days (Days 21 to 28) following Dose 2</description>
          <population>Participants who received Dose 2 (Day 21), analyzed up to Day 28.</population>
          <units>occurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number solicited local AEs (Adverse Events)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Mild solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Moderate solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Severe solicited AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With &gt;=1 (More Than or Equal to 1) Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
        <description>Number of participants with &gt;=1 mild, moderate, or severe solicited local symptoms during the 7 days (Days 0 to 7) following Dose 1</description>
        <time_frame>Days 0 to 7</time_frame>
        <population>Participants who received Dose 1 (Day 0), analyzed up to Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &gt;=1 (More Than or Equal to 1) Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
          <description>Number of participants with &gt;=1 mild, moderate, or severe solicited local symptoms during the 7 days (Days 0 to 7) following Dose 1</description>
          <population>Participants who received Dose 1 (Day 0), analyzed up to Day 7.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number solicited local AEs (Adverse Events)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Mild solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Moderate solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Severe solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With &gt;=1 (More Than or Equal to 1) Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
        <description>Number of participants with &gt;=1 mild, moderate, or severe solicited local symptoms during the 7 days (Days 21 to 29) following Dose 2</description>
        <time_frame>Days 21 to 28</time_frame>
        <population>Participants who received Dose 2 (Day 21), analyzed up to Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With &gt;=1 (More Than or Equal to 1) Mild, Moderate, or Severe Solicited Local Symptoms During the 7 Days After Each Vaccination.</title>
          <description>Number of participants with &gt;=1 mild, moderate, or severe solicited local symptoms during the 7 days (Days 21 to 29) following Dose 2</description>
          <population>Participants who received Dose 2 (Day 21), analyzed up to Day 28.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number solicited local AEs (Adverse Events)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Mild solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Moderate solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Severe solicited local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Mild, Moderate, or Severe Solicited Systemic Reactogenicity Symptoms During the 7 Days After Each Vaccination.</title>
        <description>Number of participants with mild, moderate, or severe solicited systemic reactogenicity adverse events during the 7 days (Days 0 to 7) following Dose 1</description>
        <time_frame>Days 0 to 7</time_frame>
        <population>Participants who received Dose 1 (Day 0), analyzed up to Day 7.</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mild, Moderate, or Severe Solicited Systemic Reactogenicity Symptoms During the 7 Days After Each Vaccination.</title>
          <description>Number of participants with mild, moderate, or severe solicited systemic reactogenicity adverse events during the 7 days (Days 0 to 7) following Dose 1</description>
          <population>Participants who received Dose 1 (Day 0), analyzed up to Day 7.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total no. solicited systemic AEs (Adverse Events)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="18.4" upper_limit="40.6"/>
                    <measurement group_id="O2" value="17" lower_limit="14.8" upper_limit="36.0"/>
                    <measurement group_id="O3" value="23" lower_limit="22.1" upper_limit="45.1"/>
                    <measurement group_id="O4" value="24" lower_limit="23.0" upper_limit="46.0"/>
                    <measurement group_id="O5" value="17" lower_limit="14.8" upper_limit="36.0"/>
                    <measurement group_id="O6" value="18" lower_limit="16.5" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Mild solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10.3" upper_limit="29.7"/>
                    <measurement group_id="O2" value="14" lower_limit="11.4" upper_limit="31.3"/>
                    <measurement group_id="O3" value="17" lower_limit="14.8" upper_limit="36.0"/>
                    <measurement group_id="O4" value="19" lower_limit="16.9" upper_limit="38.6"/>
                    <measurement group_id="O5" value="13" lower_limit="10.3" upper_limit="29.7"/>
                    <measurement group_id="O6" value="13" lower_limit="10.6" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Moderate solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4.1" upper_limit="19.5"/>
                    <measurement group_id="O2" value="3" lower_limit="0.9" upper_limit="12.0"/>
                    <measurement group_id="O3" value="6" lower_limit="3.2" upper_limit="17.7"/>
                    <measurement group_id="O4" value="4" lower_limit="1.6" upper_limit="13.8"/>
                    <measurement group_id="O5" value="4" lower_limit="1.6" upper_limit="14.0"/>
                    <measurement group_id="O6" value="3" lower_limit="0.9" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Severe solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O4" value="1" lower_limit="0.0" upper_limit="7.6"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="5.1"/>
                    <measurement group_id="O6" value="2" lower_limit="0.4" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With of Mild, Moderate, or Severe Solicited Systemic Reactogenicity Symptoms During the 7 Days After Each Vaccination.</title>
        <description>Number of participants with of mild, moderate, or severe solicited systemic reactogenicity adverse events during the 7 days (Days 21 to 28) following Dose 2</description>
        <time_frame>Days 21 to 28</time_frame>
        <population>Participants who received Dose 2 (Day 21), analyzed up to Day 28.</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With of Mild, Moderate, or Severe Solicited Systemic Reactogenicity Symptoms During the 7 Days After Each Vaccination.</title>
          <description>Number of participants with of mild, moderate, or severe solicited systemic reactogenicity adverse events during the 7 days (Days 21 to 28) following Dose 2</description>
          <population>Participants who received Dose 2 (Day 21), analyzed up to Day 28.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total no. solicited systemic AEs (Adverse Events)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.1" upper_limit="29.1"/>
                    <measurement group_id="O2" value="10" lower_limit="7.3" upper_limit="25.4"/>
                    <measurement group_id="O3" value="11" lower_limit="8.8" upper_limit="28.3"/>
                    <measurement group_id="O4" value="17" lower_limit="15.1" upper_limit="36.5"/>
                    <measurement group_id="O5" value="9" lower_limit="6.5" upper_limit="24.7"/>
                    <measurement group_id="O6" value="9" lower_limit="6.7" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Mild solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="5.6" upper_limit="23.5"/>
                    <measurement group_id="O2" value="10" lower_limit="7.3" upper_limit="25.4"/>
                    <measurement group_id="O3" value="10" lower_limit="7.6" upper_limit="26.5"/>
                    <measurement group_id="O4" value="11" lower_limit="8.2" upper_limit="26.7"/>
                    <measurement group_id="O5" value="5" lower_limit="2.5" upper_limit="17.0"/>
                    <measurement group_id="O6" value="9" lower_limit="6.7" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Moderate solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.0" upper_limit="13.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="1" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O4" value="6" lower_limit="3.3" upper_limit="18.0"/>
                    <measurement group_id="O5" value="4" lower_limit="1.7" upper_limit="15.0"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total no. Severe solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="5.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="5.5"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibody</title>
        <description>Geometric Mean Titer (GMT) of hemagglutination inhibition (HAI) antibody against A/Vietnam/H5N1 antigen in each study group</description>
        <time_frame>21 days after receipt of second dose of vaccine (Day 42) (plus or minus 3 days)</time_frame>
        <population>Participants who received Dose 2 (Day 28) of vaccine, analyzed at Day 42 (plus or minus 3 days).</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibody</title>
          <description>Geometric Mean Titer (GMT) of hemagglutination inhibition (HAI) antibody against A/Vietnam/H5N1 antigen in each study group</description>
          <population>Participants who received Dose 2 (Day 28) of vaccine, analyzed at Day 42 (plus or minus 3 days).</population>
          <units>antibody titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="28.7" upper_limit="50.4"/>
                    <measurement group_id="O2" value="29.6" lower_limit="22.6" upper_limit="38.9"/>
                    <measurement group_id="O3" value="37.4" lower_limit="28.3" upper_limit="49.4"/>
                    <measurement group_id="O4" value="49.4" lower_limit="37.7" upper_limit="64.8"/>
                    <measurement group_id="O5" value="19.4" lower_limit="14.6" upper_limit="25.7"/>
                    <measurement group_id="O6" value="19.9" lower_limit="13.9" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibody</title>
        <description>Geometric Mean Titer (GMT) of hemagglutination inhibition (HAI) antibody against A/Vietnam/H5N1 antigen in each study group</description>
        <time_frame>21 days after receipt of second dose of vaccine (Day 42) (plus or minus 3 days)</time_frame>
        <population>Participants who received Dose 2 (Day 28) of vaccine, analyzed at Day 42 (plus or minus 3 days).</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibody</title>
          <description>Geometric Mean Titer (GMT) of hemagglutination inhibition (HAI) antibody against A/Vietnam/H5N1 antigen in each study group</description>
          <population>Participants who received Dose 2 (Day 28) of vaccine, analyzed at Day 42 (plus or minus 3 days).</population>
          <units>antibody titers</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="5" upper_limit="320"/>
                    <measurement group_id="O2" value="40.0" lower_limit="5" upper_limit="226"/>
                    <measurement group_id="O3" value="40.0" lower_limit="5" upper_limit="453"/>
                    <measurement group_id="O4" value="56.6" lower_limit="5" upper_limit="640"/>
                    <measurement group_id="O5" value="20" lower_limit="5" upper_limit="640"/>
                    <measurement group_id="O6" value="14.1" lower_limit="5" upper_limit="905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vaccine-associated Serious Adverse Events (SAE) or Adverse Event of Special Interests (AESI)</title>
        <description>Number of participants with vaccine-associated serious adverse events (SAE) or adverse event of special interests (AESI) and occurence of AESIs or AEs leading to study withdrawal</description>
        <time_frame>First vaccination through 13 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine-associated Serious Adverse Events (SAE) or Adverse Event of Special Interests (AESI)</title>
          <description>Number of participants with vaccine-associated serious adverse events (SAE) or adverse event of special interests (AESI) and occurence of AESIs or AEs leading to study withdrawal</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccine-associated Serious Adverse Event (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Event of Special Interest (AESI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events of Special Interest (AESI) or Adverse Events (AE) Leading to Study Withdrawal.</title>
        <description>Number of participants with adverse events of special interest (AESI) or adverse events (AE) leading to study withdrawal.</description>
        <time_frame>First vaccination through approximately 13 months after first vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events of Special Interest (AESI) or Adverse Events (AE) Leading to Study Withdrawal.</title>
          <description>Number of participants with adverse events of special interest (AESI) or adverse events (AE) leading to study withdrawal.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse Event of Special Interest (AESI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events (AE) leading to study withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Adverse Events (AE)</title>
        <description>Number of participants with unsolicited adverse events (AE) through Visit 8 (Day 201)</description>
        <time_frame>Day 0 (Visit 1) through Day 201 (Visit 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events (AE)</title>
          <description>Number of participants with unsolicited adverse events (AE) through Visit 8 (Day 201)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any unsolicited Adverse Event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe unsolicited Adverse Event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Unsolicited Adverse Events (AE)</title>
        <description>Frequency of unsolicited adverse events (AE) for 21 days following Dose 1 (Days 0-21) and after Dose 2 (&gt;21 Days)</description>
        <time_frame>21 days following each vaccination (Days 0-21, &gt;21 Days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Unsolicited Adverse Events (AE)</title>
          <description>Frequency of unsolicited adverse events (AE) for 21 days following Dose 1 (Days 0-21) and after Dose 2 (&gt;21 Days)</description>
          <units>Unsolicited Adverse Events (AE)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 0-21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="179"/>
                    <measurement group_id="O3" value="186"/>
                    <measurement group_id="O4" value="202"/>
                    <measurement group_id="O5" value="156"/>
                    <measurement group_id="O6" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;21 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Clinical Safety Laboratory AEs</title>
        <description>Occurrence of clinical safety laboratory AEs at 7 and 21 days after each vaccination</description>
        <time_frame>7 and 21 days after each vaccination (Days 0, 7, 21, 28, and 42)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Clinical Safety Laboratory AEs</title>
          <description>Occurrence of clinical safety laboratory AEs at 7 and 21 days after each vaccination</description>
          <units>Clinical safety lab results reported</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3: Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7: Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT (Geometric Mean Titers) of Serum HAI (Hemagglutination Inhibition) Antibodies</title>
        <description>Overall GMTs of HAI antibodies at baseline (Day 0) and Days 21, 28 and 201</description>
        <time_frame>Day 0 (Visit 1), Day 21 (Visit 4), Day 28 (Visit 6), Day 201 (Visit 8)</time_frame>
        <population>Population receiving Dose 1 at Day 0 (Visit 1)</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>GMT (Geometric Mean Titers) of Serum HAI (Hemagglutination Inhibition) Antibodies</title>
          <description>Overall GMTs of HAI antibodies at baseline (Day 0) and Days 21, 28 and 201</description>
          <population>Population receiving Dose 1 at Day 0 (Visit 1)</population>
          <units>antibody titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="5.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5.4" lower_limit="5.0" upper_limit="5.8"/>
                    <measurement group_id="O4" value="5.2" lower_limit="4.9" upper_limit="5.6"/>
                    <measurement group_id="O5" value="5.1" lower_limit="5.0" upper_limit="5.2"/>
                    <measurement group_id="O6" value="5.3" lower_limit="4.9" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: Day 21 (+1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="9.0" upper_limit="15.4"/>
                    <measurement group_id="O2" value="8.6" lower_limit="7.0" upper_limit="10.4"/>
                    <measurement group_id="O3" value="8.7" lower_limit="6.7" upper_limit="11.4"/>
                    <measurement group_id="O4" value="14.8" lower_limit="11.1" upper_limit="19.7"/>
                    <measurement group_id="O5" value="10.8" lower_limit="8.0" upper_limit="14.6"/>
                    <measurement group_id="O6" value="14.1" lower_limit="9.6" upper_limit="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Day 28 (+1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="13.8" upper_limit="24.5"/>
                    <measurement group_id="O2" value="18.7" lower_limit="14.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="17.5" lower_limit="13.2" upper_limit="23.2"/>
                    <measurement group_id="O4" value="27.9" lower_limit="20.5" upper_limit="37.9"/>
                    <measurement group_id="O5" value="14.0" lower_limit="10.3" upper_limit="19.1"/>
                    <measurement group_id="O6" value="20.7" lower_limit="14.3" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8: Day 201 (plus or minus 7 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="67"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="5.3" upper_limit="7.2"/>
                    <measurement group_id="O2" value="5.4" lower_limit="5.1" upper_limit="5.7"/>
                    <measurement group_id="O3" value="5.5" lower_limit="5.0" upper_limit="5.9"/>
                    <measurement group_id="O4" value="5.4" lower_limit="5.1" upper_limit="5.8"/>
                    <measurement group_id="O5" value="5.9" lower_limit="5.1" upper_limit="6.8"/>
                    <measurement group_id="O6" value="6.9" lower_limit="5.6" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT (Geometric Mean Titers) of Serum Microneutralization (MN) Antibodies</title>
        <description>GMT of serum MN antibodies at baseline (Day 0) and Days 21, 28, 42 and 201</description>
        <time_frame>Day 0 (Visit 1), Day 21 (Visit 4), Day 28 (Visit 6), Day 42 (Visit 7), Day 201 (Visit 8)</time_frame>
        <population>Population receiving Dose 1 at Day 0 (Visit 1)</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>GMT (Geometric Mean Titers) of Serum Microneutralization (MN) Antibodies</title>
          <description>GMT of serum MN antibodies at baseline (Day 0) and Days 21, 28, 42 and 201</description>
          <population>Population receiving Dose 1 at Day 0 (Visit 1)</population>
          <units>antibody titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.6" upper_limit="6.6"/>
                    <measurement group_id="O2" value="5.5" lower_limit="5.2" upper_limit="5.8"/>
                    <measurement group_id="O3" value="5.5" lower_limit="5.2" upper_limit="5.7"/>
                    <measurement group_id="O4" value="6.0" lower_limit="5.6" upper_limit="6.5"/>
                    <measurement group_id="O5" value="5.4" lower_limit="5.1" upper_limit="5.7"/>
                    <measurement group_id="O6" value="5.7" lower_limit="5.4" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: Day 21 (+1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="9.3" upper_limit="16.1"/>
                    <measurement group_id="O2" value="8.0" lower_limit="6.9" upper_limit="9.3"/>
                    <measurement group_id="O3" value="10.9" lower_limit="8.4" upper_limit="14.1"/>
                    <measurement group_id="O4" value="14.2" lower_limit="11.0" upper_limit="18.4"/>
                    <measurement group_id="O5" value="10.7" lower_limit="8.2" upper_limit="13.8"/>
                    <measurement group_id="O6" value="15.4" lower_limit="10.5" upper_limit="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Day 28 (+1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="18.6" upper_limit="31.0"/>
                    <measurement group_id="O2" value="23.8" lower_limit="19.1" upper_limit="29.7"/>
                    <measurement group_id="O3" value="24.9" lower_limit="19.6" upper_limit="31.6"/>
                    <measurement group_id="O4" value="31.1" lower_limit="24.1" upper_limit="40.2"/>
                    <measurement group_id="O5" value="16.8" lower_limit="13.2" upper_limit="21.3"/>
                    <measurement group_id="O6" value="24.0" lower_limit="16.9" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7: Day 42 (plus or minus 3 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" lower_limit="39.2" upper_limit="69.7"/>
                    <measurement group_id="O2" value="43.0" lower_limit="33.8" upper_limit="54.7"/>
                    <measurement group_id="O3" value="58.8" lower_limit="45.4" upper_limit="76.1"/>
                    <measurement group_id="O4" value="66.4" lower_limit="52.3" upper_limit="84.3"/>
                    <measurement group_id="O5" value="25.0" lower_limit="20.2" upper_limit="31.0"/>
                    <measurement group_id="O6" value="30.1" lower_limit="22.0" upper_limit="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8: Day 201 (plus or minus 7 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="67"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="9.1" upper_limit="14.0"/>
                    <measurement group_id="O2" value="8.8" lower_limit="7.5" upper_limit="10.1"/>
                    <measurement group_id="O3" value="10.9" lower_limit="8.7" upper_limit="13.5"/>
                    <measurement group_id="O4" value="9.9" lower_limit="8.3" upper_limit="11.7"/>
                    <measurement group_id="O5" value="8.9" lower_limit="7.3" upper_limit="10.8"/>
                    <measurement group_id="O6" value="11.0" lower_limit="8.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum HAI (Hemagglutination Inhibition) Titer of at Least 1:40</title>
        <description>Proportion of participants achieving a serum HAI titer of at least 1:40 against the A/Vietnam/H5N1 antigen</description>
        <time_frame>Days 0 (Visit 1), 21 (Visit 4, +1day), 28 (Visit 6, +1 day), 42 (Visit 7, plus or minus 3 days), and 201 (Visit 8, plus or minus 7 days)</time_frame>
        <population>Participants who satisfied the predefined criteria for assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/G5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Serum HAI (Hemagglutination Inhibition) Titer of at Least 1:40</title>
          <description>Proportion of participants achieving a serum HAI titer of at least 1:40 against the A/Vietnam/H5N1 antigen</description>
          <population>Participants who satisfied the predefined criteria for assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 (Visit 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 (Visit 4, +1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (Visit 6, +1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 (Visit 7, plus or minus 3 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 201 (Visit 8, plus or minus 7 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="67"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate (SCR) for Hemagglutination Inhibition (HAI) Antibodies</title>
        <description>Defined as proportion of subjects achieving either a prevaccination HAI titer of &lt;1:10 and postvaccination titer of at least 1:40 or a prevaccination HAI titer of at least 1:10 and a 4-fold or greater increase of HAI postvaccination antibody titers against the A/Vietnam/H5N1 antigen; if baseline HAI titer is undetectable, it will be assigned a vaue of half the lower limit of detection.</description>
        <time_frame>Days 21, 28, 42, and 201</time_frame>
        <population>Participants who satisfied the predefined criteria</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) for Hemagglutination Inhibition (HAI) Antibodies</title>
          <description>Defined as proportion of subjects achieving either a prevaccination HAI titer of &lt;1:10 and postvaccination titer of at least 1:40 or a prevaccination HAI titer of at least 1:10 and a 4-fold or greater increase of HAI postvaccination antibody titers against the A/Vietnam/H5N1 antigen; if baseline HAI titer is undetectable, it will be assigned a vaue of half the lower limit of detection.</description>
          <population>Participants who satisfied the predefined criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4: Day 21 (+1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="65"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Day 28 (+1day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7: Day 42 (plus or minus 3 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8: Day 201 (plus or minus 7 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="67"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate (SCR) for Microneutralization (MN) Antibodies</title>
        <description>Defined as proportion of subjects achieving either a prevaccination MN titer of &lt;1:10 and postvaccination titer of at least 1:40 or a prevaccination MN titer of at least 1:10 and a 4-fold or greater increase of MN postvaccination antibody titers against the A/Vietnam/H5N1 antigen; if baseline MN titer is undetectable, it will be assigned a vaue of half the lower limit of detection.</description>
        <time_frame>Days 21, 28, 42, and 201</time_frame>
        <population>Participants who satisfied the predefined criteria</population>
        <group_list>
          <group group_id="O1">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
          </group>
          <group group_id="O2">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
          </group>
          <group group_id="O3">
            <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O4">
            <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
            <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
          </group>
          <group group_id="O5">
            <title>90 mcg H5N1 (Monobulk) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
          </group>
          <group group_id="O6">
            <title>90 mcg H5N1 (Vials) Without MF59</title>
            <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) for Microneutralization (MN) Antibodies</title>
          <description>Defined as proportion of subjects achieving either a prevaccination MN titer of &lt;1:10 and postvaccination titer of at least 1:40 or a prevaccination MN titer of at least 1:10 and a 4-fold or greater increase of MN postvaccination antibody titers against the A/Vietnam/H5N1 antigen; if baseline MN titer is undetectable, it will be assigned a vaue of half the lower limit of detection.</description>
          <population>Participants who satisfied the predefined criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 4: Day 21 (+1 day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Day 28 (+1day)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7: Day 42 (plus or minus 3 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="69"/>
                    <count group_id="O5" value="64"/>
                    <count group_id="O6" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 8: Day 201 (plus or minus 7 days)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="67"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event (AE) data were collected from Visit 1 (Day 0) through Visit 7 (Day 42); Adverse Events of Special Interest (AESI) and Serious Adverse Events (SAEs) were assessed from Visit 1 (Day 0), until exit from the study, Visit 9 (Day 386). Data currently available to Visit 8 (Day 201).</time_frame>
      <desc>Subjects recorded solicited local and systemic reactions to the vaccine or adjuvant, and other unsolicited symptoms or complaints, including start and stop dates, on an 8-day diary card following each of the 2 vaccinations. Diary cards captured unsolicited AEs for 21 days after each vaccination. Regular investigator assessment at each visit, except Visit 1. Abnormal laboratory test results judged clinically significant by investigator recorded as AEs or SAEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as bulk MF59 adjuvant</description>
        </group>
        <group group_id="E2">
          <title>15 mcg H5N1 (Monobulk) Plus MF59 (Monobulk)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long term as monobulk MF59 adjuvant</description>
        </group>
        <group group_id="E3">
          <title>7.5 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
        </group>
        <group group_id="E4">
          <title>15 mcg H5N1 (Monobulk) Plus MF59 (Vials)</title>
          <description>Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short term in vials as MF59 adjuvant</description>
        </group>
        <group group_id="E5">
          <title>90 mcg H5N1 (Monobulk) Without MF59</title>
          <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59</description>
        </group>
        <group group_id="E6">
          <title>90 mcg H5N1 (Vials) Without MF59</title>
          <description>Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Left foot.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <description>Left fifth metatarsal.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Injury resulting from motor vehicle accident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastrointestinal organ contusion</sub_title>
                <description>Injury resulting from motor vehicle accident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <description>Injury resulting from motor vehicle accident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <description>Injury resulting from motor vehicle accident.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <description>Joint dislocation (left hip) determined to be displaced prosthesis.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <description>Left foot.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pseudomeningocele</sub_title>
                <description>Pseudomeningocele diagnosed post-operatively following anterior/posterior cervical fusion with plating, and a C5-6 right hemilaminectomy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="71"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="70"/>
                <counts group_id="E6" subjects_affected="47" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="71"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="70"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="71"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="70"/>
                <counts group_id="E4" events="33" subjects_affected="33" subjects_at_risk="71"/>
                <counts group_id="E5" events="25" subjects_affected="25" subjects_at_risk="70"/>
                <counts group_id="E6" events="29" subjects_affected="29" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="70"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="71"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="71"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E6" events="12" subjects_affected="12" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="71"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <description>General disorders and administration site conditions</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="71"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="70"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="71"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="70"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="71"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="70"/>
                <counts group_id="E6" events="17" subjects_affected="17" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Data and results owned by Sponsor. Results can be used by Institution for (a) internal non-commercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Protocol implied Clinical Study Report (CSR) would include Day 386 (end-of-study) data. Following start of study it was decided CSR would include data up to and including Day 201. CSR addendum will include data from Day 201-Day 386.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Silvija Tresnjak-Smith</name_or_title>
      <organization>BARDA</organization>
      <phone>202-557-1993</phone>
      <email>Silvija.Tresnjak-Smith@hhs.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

